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Abstract
Trabosh, Savannah Marie. MS. The University of Memphis. May, 2015. The Effects of a
Selective D2 Dopamine Receptor Agonist and Antagonist on D2 Autoreceptor-Mediated
Inhibition of Dopamine Release in the Mouse Nucleus Accumbens. Major Professor: Dr.
Charles Blaha
This study examined the function of D2 autoreceptors under the influence of a
selective dopamine D2 receptor agonist (quinpirole) and antagonist (sulpiride).
Inhibition of medial forebrain bundle (MFB) stimulation-evoked dopamine release by
activation of D2 autoreceptors was investigated in the nucleus accumbens (NAc) of
urethane-anesthetized mice using fixed potential amperometry. Trains of electrical
stimulation (5-40 pulses at 15 Hz) were applied to the MFB to endogenously activate D2
autoreceptors. Systemic administration of sulpiride blocked D2 autoreceptor-mediated
inhibition of dopamine release in the NAc. Intra-NAc microinfusion of quinpirole by
itself did not affect D2 autoreceptor-mediated inhibition of dopamine release. However,
following pretreatment with sulpiride, intra-NAc microinfusions of quinpirole were
effective in augmenting D2 autoreceptor-mediated inhibition of dopamine release.
Together, these results suggest that short-term blockade of D2 autoreceptors in the NAc
by a selective D2 receptor antagonist enhances the response of these receptors to a
selective D2 agonist.
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The Effects of a Selective D2 Dopamine Receptor Agonist and Antagonist on D2
Autoreceptor-Mediated Inhibition of Dopamine Release in the Mouse Nucleus
Accumbens
Central Dopaminergic Systems
Dopamine (DA) serves as a neurotransmitter in a number of midbrain to
subcortical and cortical neuronal projections and is responsible for a variety of functions
that include attention, executive function, reinforcement responses, motivation, and
movement (Gowrishankar, Hahn, Blakely, 2013). Of these neuronal projections
containing dopamine, the dopaminergic mesolimbic (specifically the mesoaccumbens)
neuronal pathway plays a particularly important function in mediating incentivemotivation, goal-directed behaviors, and reward processing (Da Cunha, Gomez-A, Blaha,
2012; Dichter, Damiano, Allen, 2012). This neuronal pathway originates in the ventral
tegmental area (VTA) of the midbrain and ascends rostrally to the nucleus accumbens
(NAc) in the forebrain via the medial forebrain bundle (MFB; Phillips, 2003).
Pharmacology of the D2 Dopamine Receptor
The actions of DA at its neuronal target sites in the brain are mediated by five
different DA receptor subtypes: D1, D2, D3, D4, and D5. These receptors are grouped
into D1-like, that include receptors D1 and D5, and D2-like, that include receptors D2,
D3, and D4, according to their structural, pharmacological, and biochemical properties
(Beaulie & Gainetdinov, 2011). The D2 receptor subtype is expressed both
presynaptically and postsynaptically in the NAc and on dopaminergic cell dendrites in the
VTA (Ford, 2014). D2 receptors display a wide range of affinity to different DA
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agonists/antagonists (Beaulieu & Gainetdinov, 2011). Due to this range of affinity, this
receptor is often a pharmacological target in the treatment of psychiatric illnesses, most
notably schizophrenia (Ford, 2014). The D2 receptors are also of considerable interest
because structural abnormalities have been identified in D2 receptors whose activation by
DA may underlie some of the positive behavioral symptoms of schizophrenia (Beaulier &
Gainetdinov, 2011).
As noted above, D2 receptors can function as both presynaptic autoreceptors and
postsynaptic receptors. Autoreceptors function presynaptically to regulate DA
transmission by inhibiting DA release, decreasing DA synthesis, and changing the uptake
of DA within the dopaminergic terminal (Ford, 2014). Therefore, activation of DA
autoreceptors, either by an endogenous agonist or DA itself, inhibits subsequent DA
neurotransmission. In contrast, blockade of DA autoreceptors by an antagonist results in
an enhancement of subsequent DA neurotransmission. Clinically, a number of dopamine
receptor antagonist drugs (e.g., sulpiride) have proven effective as antipsychotic
medications to control positive psychotic symptoms (Mhyre et al., 2014).
D2 Activation Modulates Conditioned Avoidance Responses
Avoidance is a form of behavior that prevents an aversive event (Boschen
Wietzikoski, Winn, Da Cunha, 2011). By avoiding an aversive event, there is negative
reinforcement and motivation to avoid the event a second time, if presented. A deficit in
Conditioned Avoidance Responses (CARs) in human patients has been found with most
antipsychotic medications (Wadenberg, 2010). As noted above, the role of NAc DA in
rewarding motivated actions is well established, but its role in learning how to avoid
aversive events remains controversial. Previous research completed by Boschen et al.
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(2011) utilized CAR in rats following administration of high and low doses of the
selective D2 agonist quinpirole. Among the number of findings of this study that were
germane to the present study were: (1) a relatively low dose of quinpirole (10 µg) infused
into the NAc core of rats decreased the number of CARs and increased the number of
escape failures and (2) a relatively higher dose of quinpirole (50 µg) infused into the NAc
core increased the number of CARs. These investigators postulated that the low dose of
quinpirole inhibited NAc DA release via selective activation of presynaptic DA D2
autoreceptors, whereas the higher dose of quinpirole activated postsynaptic DA D2
receptors. Using neurochemical recording techniques, the present study will address this
issue as to whether low doses of quinpirole can effectively activate DA D2 presynaptic
autoreceptors to inhibit DA neurotransmission.
Current Study
The current study investigated the sensitivity of D2 autoreceptors to the D2
agonist quinpirole. It was hypothesized that a relatively low dose of intra-NAc quinpirole,
similar to that employed by Boschen et al. (2011), would act on presynaptic D2
autoreceptors to effectively inhibit MFB stimulation-evoked NAc DA release, while
systemic administration of the D2 antagonist sulpiride would, by itself, enhance MFB
stimulation-evoked NAc DA release. It was further hypothesized that pretreatment with
sulpiride would effectively block the inhibitory effects of quinpirole on MFB stimulationevoked NAc DA release due to competitive binding at D2 autoreceptors. Specifically,
the current study examined the function of D2 autoreceptors under the influence of a
selective DA D2 receptor agonist (quinpirole) and antagonist (sulpiride).
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Methods
Animals
Ten adult male DBA/2J mice weighing between 28-36g from the Department of
Psychology, University of Memphis (Memphis, TN) breeding stock were used. Mice
were maintained in a temperature-controlled room at 22±2ºC on a 12-sulpiride light/dark
cycle with lights on, 7:00 a.m. The animals had water and food available ad libitum.
The University of Memphis Institutional Animal Care and Use Committee approved all
procedures. Procedures were also in accordance with the guidelines of the Public Health
Service Policy on Humane Care and Use of Laboratory Animals (National Institutes of
Health, 2002), the Guidelines for the Care and Use of Mammals in Neuroscience and
Behavioral Research (National Research Council, 2003), and the Brazilian law (11.794/8
October 2008).
Fixed Potential Amperometry (FPA)
DA release in the NAc was recorded in vivo using a commercially available
hardwired electrochemical recording system (eDAQ, Pty Ltd) consisting of a potentiostat
(EA161 Picostat) in conjunction with an analog-to digital signal converter-recorder (ecorder). For every molecule of DA that was oxidized (as a result of release), two
electrons were transferred to the recording electrode. An A/D converter was used to
convert the changes in DA oxidation current to a digital voltage signal that allowed the
stimulation-evoked changes in DA release to be observed in real time.
Surgery
Mice were anesthetized with urethane (1.5 g/kg, i.p.). Once fully anesthetized,
mice were mounted in a stereotaxic head-holder and frame (David Kopf Instruments,
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Tujunga, CA) within a Faraday cage. They were maintained at 36 ± 0.5°C throughout
FPA procedure with the use of a heating pad. The cranium was exposed and three holes
were drilled. Two holes were drilled unilaterally and one hole contralaterally using a
dental drill. A concentric bipolar stimulating electrode (SNE-100; Rhodes Medical Co.,
CA) was implanted into the medial forebrain bundle (MFB coordinates in mm: -2.1 AP
from bregma; -1.1 ML from midline -4.8 DV from dura mater). A carbon fiber electrode
(250 μm length × 10 μm o.d.; Thornel Type P, Union Carbide, Pittsburgh, PA) was
placed into the ipsilateral NAc core (coord. in mm: +1.2AP from bregma; -0.7ML from
midline; -3.8DV from dura mater) (Franklin and Paxinos, 1997). An Ag/AgCl
reference/auxiliary combination electrode was placed on contralateral cortical tissue -3.0
mm from bregma. A delay of 10-20 minutes allowed the recording electrode to stabilize
before the start of the experiment.
Activation of D2 Autoreceptors by Conditioning Stimuli (CS)
The procedure to measure DA release by conditioning stimuli using FPA has been
validated by Benoit-Marand et al. (2001). Variance in DA release was determined by
applying a pair of test stimuli (T1 and T2; with ten 0.5ms duration 800 μA pulses at 50
Hz separated by 10s) to the MFB six times every 30s to evoke DA efflux in the NAc.
Four sets of conditioning stimuli (5, 10, 20, and 40 pulses) (0.5ms pulse duration at 15
Hz) mimicking spontaneous action potential frequency of midbrain DA neurons were
given prior to T2 such that there was 0.3s between the end of the conditioning pulse train
and initiation of T2. Between trials, the next T1 stimulus occurred approximately 20s
after the previous T2 stimulus and was recorded in the absence of any conditioning pulses,
thereby serving as a moving baseline response (100%). The effects of the conditioning
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pulses on T2-stimulated DA efflux relative to T1 were measured in ascending order (i.e.,
the effects of 5 conditioning pulses were determined first, followed by 10 conditioning
pulses, followed by 20, and then 40). This allowed for the determination of the effect of
each conditioning pulse train on stimulation-evoked DA release corresponding to T2.
The entire sequence took approximately 10 min to complete.
Materials and Design
Sulpiride (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 10-ml/kg-body
weight acidified saline (0.9% NaCl). Low (3mg/kg) and high (50mg/kg) systemic doses
of sulpiride were chosen based on previous experiments of the Da Cunha laboratory
(Boschen et al. 2011, Boschen, Andreatini, Da Cunha 2015) and from other studies
(Centonze et al., 2009; Gubernator et al., 2009; Rodgers et al., 1994). The doses were
chosen based on previous research, the efficacy of the dose on behavior, and allowed for
a more exact replication and further examination of the behavioral study regarding CARs
(Boschen et al., 2011). It should also be noted that according to the hypothesis presented
by Boschen and colleagues (2011), a higher does of quinpirole is believed to act
postsynaptically on D2 receptors and since the purpose of this research is to examine
presynaptic autoreceptor function, the lower dosage of quinpirole was sufficient.
Quinpirole (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 0.2µl saline as
previously used by Grilli et al. (2009).
Evoked DA release by the CS procedure was delivered before drug treatment;
therefore, each mouse served as its own control. Immediately after the end of the first
sequence, sulpiride (3 or 50mg/kg) was intraperitonealy (i.p.) administered and
stimulations were restarted and recorded 15 minutes post injection. Quinpirole was
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microinfused into the NAc through a silica capillary before stimulations restarted. The
premise for these drug treatments was to examine the effects of these drugs on D2
autoreceptor inhibition of MFB stimulation-evoked DA release. By administering a CS,
D2 autoreceptors are stimulated, inhibiting DA release. As the number of CS increases,
the greater the activation of D2 autoreceptors by endogenous DA. Administering
sulpiride prior to quinpirole was intended to initiate competitive binding to block
autoreceptor function and thereby increases DA release. Simultaneous administration of
a CS and injection of the drugs allowed for the observation of DA release in real time via
FPA procedures.
The present study utilized three different conditions. Three mice received i.p.
injections of saline followed by intra-NAc quinpirole. Three mice received 3mg/kg
sulpiride i.p. injection followed by 10μg quinpirole intra-NAc. Four mice received
50mg/kg sulpiride i.p. injection followed by 10μg quinpirole intra-NAc.
Histology
At the end of the experimental procedures, all mice received a lesion through the
stimulating electrode. To check for electrode placement, all brains were soaked with a
saline solution followed by 4% paraformaldehyde. Brains were then prepared for
microtome sectioning (40 µm thick slices) on a cryostat to identify placement of the
stimulating and recording electrodes.
Analysis
All data were analyzed using GraphPad Software (La Jolla, USA). Effects of
drug treatments on inhibition of DA release or D2 autoreceptor sensitivity were analyzed
via one-way ANOVA or two-way ANOVA when appropriate. T2 peak stimulated DA
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release was be expressed as a percent change from 100% baseline T1 responses were
analyzed using a between-subjects one-way ANOVA for treatment group (10μg
quinpirole, 10μg quinpirole and 3 mg/kg sulpiride, 10μg quinpirole and 50 mg/kg
sulpridie). D2 autoreceptor sensitivity was expressed as a percent change from baseline
and analyzed using a mixed two-way ANOVA for treatment group (10μg quinpirole,
10μg quinpirole and 3 mg/kg sulpiride, 10μg quinpirole and 50 mg/kg sulpridie) and
number of pulses (5, 10, 20, and 40 pulses at 15 Hz). Additional Newman-Keuls post
hoc analyses were conducted to determine the nature of significant effects treatment
revealed.
Results
Histology
Light microscope examination of brain tissue slices revealed that all carbon fiber
recording electrodes were accurately placed within the NAc core ranging from 1.18 mm
(5 mice) to 1.34 mm (3 mice) and 1.42 mm (2 mice) anterior to bregma in accordance
with the mouse brain atlas of Franklin and Paxinos (1997) (see Figure 1A). All mice (n =
10) had the tip of the stimulating electrode accurately placed within the MFB with seven
stimulating electrodes located within the MFB at 1.9 mm posterior to bregma and three at
2.0 mm posterior to bregma (Franklin and Paxinos, 1997) (see Figure 1B).
Fixed Potential Amperometry
Typical amperograms of MFB stimulation-evoked DA release in the NAc are
illustrated in Figure 2. DA release evoked by 15 Hz CS pulses (5-40 pulses) inhibited
MFB stimulation-evoked DA release in the NAc. It was expected that increased DA
release (i.e., increasing number of applied CS pulses) would have a progressively greater
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inhibitory effect on the test (T2) stimulation, however as shown in Figure 2 D2
autoreceptor mediated inhibition reached a maximal effect by 5 to 10 CS pulses.
Effects of Sulpiride and Quinpirole on T1
DA release occurring during the application of T1 stimulation would be expected
to act on D2 autoreceptors, thus dampening the overall magnitude of this evoked
response. Thus, it was expected that blockade of D2 autoreceptors by systemic injection
of sulpiride would result in an enhancement of MFB stimulation-evoked DA release.
Accordingly, as shown in Figure 3, systemic administration of sulpiride increased MFB
stimulation-evoked DA release (T1) in a dose dependent manner. This effect was
significantly reversed by intra-NAc infusion of quinpirole with a dose that did not affect
DA release by itself [F (5,85) = 7.52; p < 0.05, ANOVA], suggesting that blockade of D2
autoreceptors by the antagonist sulpiride may have sensitized these receptors to the DA
agonist (quinpirole) and possibly even to endogenous DA.
Effects of Sulpiride and Quinpirole on T2
Additional measures determined the responsivity of D2 autoreceptors to a
relatively low dose of quinpirole following progressive increases in CS pulses. Even a
relatively moderate amount of DA release evoked by 5 CS pulses caused an immediate
inhibition of MFB stimulation-evoked DA release (T2) in the NAc (see Figure 4).
However, a progressive increase in the number of CS pulses (10 and 20 CS) did not result
in a greater inhibitory effect, suggesting that maximum activation of the D2 autoreceptors
was attained with synaptic concentrations of DA evoked by 5 CS pulses. However, after
40 CS, a significantly greater magnitude of inhibition was observed [F (4,64) = 35.84, p <
0.05, ANOVA].
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If the inhibition of MFB stimulation-evoked DA release (T2) shown in Figure 4
were dependent on the activation of the D2 autoreceptors, the D2 selective antagonist
sulpiride would be expected to block this D2 autoreceptor mediated inhibition of T2.
This prediction was tested under two conditions: after 5 CS, where a relatively low level
of DA is released before T2; and after 40 CS, where a relatively larger amount of DA is
released before T2. Data was normalized by T2 of the control (untreated) group and are
shown in Figure 5. Under both conditions (after 5 CS and 40 CS) 3 mg/kg sulpiride
treatment did not reduce T2, however 50 mg/kg sulpiride caused a significant increase of
T2, suggesting a 3 mg/kg dose of sulpiride was insufficient to displace DA from D2
autoreceptors. Furthermore, infusion of 10µg quinpirole into the NAc of the sulpiridepretreated mice caused a significant reduction of T2 compared to the groups treated only
with 3 or 50 mg/kg sulpiride, respectively. One-way ANOVA showed significant effects
of the drug treatments effects after 5 CS [F (5,85) = 14.04; p < 0.05] and 40 CS [F (5,85)
= 13.03; p < 0.05]. It is worth noting that the inhibitory effects of quinpirole on T2 were
unmasked in the presence of 3 mg/kg of sulpiride, whereas quinpirole alone effectively
antagonized the magnitude of T2.
The effects of quinpirole and sulpiride on T2 shown in Figure 5 suggest that they
affected presynaptic D2 autoreceptor-mediated inhibition of T2. Running separate twoway ANOVAs for quinpirole and sulpiride data tested this hypothesis. In each ANOVA,
the drug treatment and the number of pulses used as CS were taken as independent
factors. Significant effects were observed for quinpirole treatment [F (1,17) = 26.48; p <
0.05], CS [F (3,51) = 11.36; p < 0.05], and of the quinpirole treatment by CS interaction
[F (3,51) = 5.83; p < 0.05]. In addition, significant effects were observed for CS [F
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(3,51) = 5.90; p < 0.05], sulpiride treatment [F (2,34) = 5.04; p < 0.05], and the
interaction CS by sulpiride treatment [F (6,102) = 3.86; p < 0.05].
Discussion
In this study, the inhibition and activation of D2 autoreceptors and their relative
sensitivity to endogenously released DA were investigated. Intra-NAc microinfusion of
10µg of the selective D2 receptor agonist quinpirole by itself did not inhibit MFB
stimulation-evoked DA release. In contrast, systemic (i.p.) administration of the D2
selective antagonist sulpiride at the doses of 3 and 50 mg/kg significantly enhanced MFB
stimulation-evoked DA release. These findings clearly illustrate the negative feedback
(inhibitory) role of D2 autoreceptors in regulating phasic increases in DA
neurotransmission in the NAc. Quite unexpectedly however, pretreatment with either a
low or relatively high dose of sulpiride resulted in a dose-dependent inhibition of MFB
stimulation-evoked DA release by quinpirole (see Figure 3). Together, these results
suggest that short term blockade of D2 autoreceptors (via pretreatment with sulpiride)
enhances their sensitivity to subsequent activation by a D2 agonist, such as quinpirole.
Overall, D2 autoreceptor sensitivity was determined by applying a train of
increasing number of pulses (CS, 5 to 40 pulses at 15 Hz) immediately prior to a test train
of stimulation (T2) of the MFB. This procedure was applied to evoke a progressively
increasing synaptic concentration of DA so as to maximally activate D2 autoreceptors
prior to a test stimulation of the MFB (Mittleman et al., 2011). The rational is that as the
number of CS pulses increase, the degree of D2 autoreceptor activation would reach a
maximum inhibition of the subsequent MFB test stimulation-evoked DA release and
serve as a measure of overall D2 autoreceptor sensitivity. The present results
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demonstrated that maximal D2 autoreceptor activation was achieved with the application
of 5-20 CS pulses. However, compared to the magnitude of inhibition of T2 with 5-20
CS pulses, the application of 40 CS pulses resulted in a significantly greater inhibition of
T2. These results suggest that 40 CS pulses may result in relatively greater DA release
that may activate extrasynaptic D2 autoreceptors (Tanaka,Vincent, Nomikos, Fibiger,
1992) to lead to greater inhibition of the test stimulus T2 (see Figure 4).
The present study examined further the relative sensitivity of D2 autoreceptor
activation by CS pulses in the NAc following their selective blockade and activation by a
D2 antagonist (sulpiride) and agonist (quinpirole). Intra-NAc microinfusion of
quinpirole alone had no effect on CS-mediated (5 to 40 pulses) inhibition of MFB
stimulation-evoked DA release (T2). In addition, systemic administration of sulpiride at
the dose of 3 mg/kg also did not affect CS-mediated (5 to 40 pulses) inhibition of MFB
stimulation-evoked DA release (T2). In contrast, systemic administration of sulpiride, at
a relatively higher dose of 50 mg/kg, significantly prevented the inhibition of T2 by 5 to
40 CS pulses. Most interestingly, intra-NAc quinpirole was able to enhance 5 and 40 CS
pulse-induced inhibition of T2, but only following systemic administration of sulpiride at
either the dose of 3 or 50 mg/kg. These novel, previously unreported results suggest that
relatively low dose and short term blockade of D2 autoreceptors by a D2 receptor
antagonist (in this case sulpiride) may increase the efficacy of a D2 dopamine agonist (in
this case quinpirole) (see Figure 5).
The present study hypothesized that a relatively low dose of intra-NAc quinpirole,
similar to that employed by Boschen et al. (2011), would act on presynaptic D2
autoreceptors to effectively inhibit MFB stimulation-evoked NAc DA release. As shown
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recently by Boschen et al. (2011), a relatively low dose of quinpirole (10 µg) infused into
the NAc core of rats decreased the number of CARs and increased the number of escape
failures, whereas a relatively higher dose of quinpirole (50 µg) infused into the NAc
increased the number of CARs. Based on these results, these investigators concluded that
the differences in behavioral outcome observed with these two doses of quinpirole were
due to the differential actions of quinpirole on pre- versus postsynaptic DA receptors in
the NAc. Thus, it was postulated that the low dose of quinpirole inhibited NAc DA
release via selective activation of presynaptic DA D2 autoreceptors, whereas the higher
dose of quinpirole activated postsynaptic DA D2 receptors. However, the present study
found that a relatively low dose of quinpirole microinfused into the NAc failed to inhibit
MFB stimulation-evoked DA release or augment the inhibition of MFB evoked DA
following application of a train of pulse stimulations (CS) intended to prime and activate
DA autoreceptors. Most interestingly, quinpirole appeared only effective in inhibiting
MFB stimulation-evoked DA release following short-term blockade of D2 autoreceptors
by systemic pretreatment with the D2 receptor antagonist sulpiride. Under the present
experimental conditions, relatively short term D2 autoreceptor blockade may have
sensitized these receptors to quinpirole thereby augmenting the presynaptic inhibitory
actions of this agonist. With respect to the Boschen and coworker studies, these results
altogether suggest that their behavioral observations (decreased number of CARs and
increased number of escape failures) following a low intra-NAc dose of quinpirole were
likely mediated by a mechanism other than presynaptic D2 autoreceptor activation and
accompanying decrease in DA synaptic release. It is also conceivable that, in addition to
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D2 autoreceptors, there may be additional means of presynaptic regulation of DA
neurotransmission.
One possibility for Boschen and coworker’s observations of the behavioral effects
of a low dose of quinpirole is that DA autoreceptor function is, at least partly, dependent
on activation of D3 DA presynaptic receptors. In addition to D2, D3 receptors also
function as autoreceptors in the regulation of DA release (Gainetdinov et al., 1994;
Joseph et al., 2002; Sokoloff, Giros, Martres, Bouthene, Schwartz, 1990; Tepper, Sun,
Martin, Creese, 1997). Similar to D2 receptor distribution, D3 receptor distribution is
largely in the NAc (Booze & Wallace, 1995; Gurevich & Joyce, 1999). Zheng et al.
(2011) have shown that quinpirole may weakly bind to D3 receptors. Indeed, other
investigators have also shown that quinpirole is a D2 agonist with partial selectivity to D3
receptor, whereas DA has equivalent selectivity to D2 and D3 receptors (BolañosJiménez et al.; 2011; Fliestra & Levant, 1998). Taken together, it is possible that
saturation induced by DA was mediated by D3, but not D2 activation. In order to better
understand the role of D3 receptors in the mediation of D2 autoreceptor activation, it
would be beneficial for future research to examine D3 knockout mice. For instance, to
examine the possible inhibitory role D3 receptors play in behavior Pritchard and
colleagues (2003) utilized D3 knockout mice and found significant differences in the
behavior with D3 knockout mice compared to wild-type mice suggesting that it is
possible that both D2 and D3 receptors have an inhibitory role in the regulation of DA.
In addition, the inhibitory role of D3 autoreceptors on MFB stimulation-evoked DA and
CS pulse primed inhibition of MFB stimulation-evoked DA release could be examined by
determining the effects of intra-NAc microinfusions of selective D3 receptor agonists,
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such as 7-OH-DPAT or PD 128907 (Pritchard et al., 2003), alone or in combination with
quinpirole.
In addition to the potential contribution of presynaptic D3 autoreceptors to the
behavioral effects observed by Boschen and coworkers with a low dose of quinpirole, it
is important to note that the methodology employed in the present experiment (FPA) may
not be the most effective measure because FPA measures electrical stimulation-evoked
(phasic) DA release and not basal (tonic) DA release. This distinction is important
because previous in vivo microdialysis studies have shown that relatively low dose
application of quinpirole into the NAc effectively decreases basal extracellular
concentrations of DA (Ferré & Artigas, 1995; Rahman & McBride, 2001). Thus it is
conceivable that a reduction in basal, rather than phasic, extracellular DA levels by a low
dose of quinpirole via activation of D2/3 autoreceptors may account for their behavioral
observations (decreased the number of CARs and increased the number of escape
failures).
Conclusion
The main goal of this study was to examine the effects of the selective D2 agonist
quinpirole on the inhibition of phasic (stimulation) evoked NAc DA release via activation
D2 autoreceptors. It was hypothesized that a relatively low dose of the D2 agonist
quinpirole would selectively activate NAc D2 autoreceptors to inhibit the release of MFB
stimulation-evoked DA. Specifically, it was found that the dose of quinpirole employed
was effective at inhibiting evoked DA release only after systemic administration of the
D2 antagonist sulpiride, suggesting that short term blockade of these receptors is required
for these inhibitory effects of quinpirole. Recognizing the distinction between the present
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study and that of Boschen et al. (2011) (i.e., effects of quinpirole on basal versus phasic
DA release), it would be important to compare these findings with future studies utilizing
methodologies to measure changes in basal DA release in the NAc (e.g., in vivo
microdialysis).
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Appendix

Figure 1 Localization of recording and stimulating electrodes in the mice NAc core (A)
and MFB (B). Adapted from Franklin and Paxinos, 1997.
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Figure 2. Typical amperograms showing D2 autoreceptor-induced inhibition of medial
forebrain bundle stimulation-evoked (10 pulses, 800 µA, 50 Hz) DA release and
desensitization of D2 autoreceptors of the NAc.
The first peak (T1) of DA release serves as the within response control. When the
same stimulus used to evoke T1 was preceded by conditioning stimuli (CS, 5, 10, 20 and
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40 pulses, 800 µA, 15 Hz) inhibition of the second DA peak (T2) in relation to T1 was
observed. However, inhibition did not increase with increasing number of applied CS
pulses suggesting maximal activation of D2 autoreceptors were attained at 10 CS pulses.

Figure 3. Effects of systemic administration of quinpirole, sulpiride and their
combination on MFB stimulation-evoked DA release in the NAc core.
Data were collected from 10 mice and represents the mean ± SEM area under the
curve of the amperograms (T1 from Fig. 2 normalized by the control). DA release by a
train of 10 electric pulses of 800 μA, 0.5ms each, at 50 Hz applied to the medial forebrain
bundle. The numbers of amperograms for each group were: control (N= 18); quinpirole
10μg intra-NAc (Qui 10, N =18); sulpiride 3mg/kg i.p. (Sulp3, N = 18); sulpiride
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50mg/kg i.p. (Sulp 50, N = 18). * p < 0.05 compared to control; + p < 0.05 compared to
sulpiride 3 or sulpiride 50, respectively; Newman-Keuls after one-way ANOVA.

Figure 4. D2 autoreceptor inhibition.
Data were collected from the 3 mice from the control group (N = 18
amperograms) and represents the mean ± SEM area under the curve (T1 for Baseline and
T2 for 5-40 CS normalized by T1; T1 and T2 are illustrated in Fig.2). * p < 0.05
compared to Baseline; # p < 0.05 compared to 5 CS; + p < 0.05 compared 10 CS; § p <
0.05 compared to 20 CS.
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Figure 5. Effects of sulpiride and quinpirole on MFB stimulation-evoked DA release
inhibition induced by activation of D2 autoreceptors using 5 and 40 CS pulses.
The relative change in the area of T2 (ten 0.5ms duration 800 μA pulses at 50 Hz)
after 5 and 40 CS (0.5ms pulse duration at 15 Hz) pulses shows the effects of drug
treatments on DA release inhibition by D2 autoreceptors. Data were collected from 10
mice and the number of amperograms for each group was: control (N= 18); quinpirole
10μg intra-NAc (Qui 10, N =18); sulpiride 3mg/kg i.p. (Sulp3, N = 18); sulpiride
50mg/kg i.p. (Sulp 50, N = 18). Data are expressed as mean ± SEM. * p < 0.05 compared
to control; + p < 0.05 compared to the respective sulpiride dose (Sulp3 or Sulp50); # p <
0.05 compared to Qui10.
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